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Although protein lysine acetylation was first discovered almost 
50 years ago on nuclear histones (Phillips, 1963; Allfrey et al., 
1964, 1968), the broad involvement of this reversible covalent 
modification in cell regulation has only been appreciated during 
the past five years. The discovery that large numbers of cellular 
proteins are acetylated was made possible by the rapid devel­
opment of mass spectrometric technology during this period. 
Using an improved immunopurification scheme to enrich for 
acetylated peptides, Kim et al. (2006) first identified 388 lysine 
acetylation sites corresponding to 195 distinct proteins from 
mouse liver tissue and HeLa cells. Notably, 277 acetylated 
peptides were derived from 133 proteins located within the mito­
chondrion, including many intermediary metabolic enzymes. 
This was a rather surprising finding because previous lysine 
acetylation studies had primarily identified nuclear proteins. 
Two subsequent acetylation proteomic studies, using similar 
methods, significantly expanded the acetylome of mammalian 
cells and identified an astonishing 1,750 acetylated proteins 
from three different human cancer cell lines (Choudhary et al., 
2009) and 978 acetylated proteins from human liver tissue after 
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excluding nuclear protein (Zhao et al., 2010). Together, these 
three acetylation studies identified >2,000 acetylated proteins 
in mammalian cells, making the regulatory scope of acetylation 
comparable to those by other major posttranslational modifica­
tions such as phosphorylation and ubiquitylation (Choudhary 
and Mann, 2010; Guan and Xiong, 2011).
These acetylated proteins span a wide spectrum of protein 
classes, ranging from transcription factors to kinases, ubiquitin 
ligases, ribosomal proteins, structural proteins, and metabolic 
enzymes, all of which cover a broad range of cellular activi­
ties from cell cycle control, DNA damage checkpoints, and cyto­
skeleton organization to endocytosis and metabolism. Owing to 
the use of liver, the major metabolic organ in the body, as the 
tissue source by two of these acetylation proteomic studies, 
many metabolic enzymes were found to be potentially acetylated. 
Nearly all enzymes involved in glycolysis, gluconeogenesis, 
the TCA cycle, fatty acid oxidation, the urea cycle, nitrogen 
metabolism, and glycogen metabolism are acetylated (Zhao 
et al., 2010). Enzymes involved in oxidative phosphorylation 
and amino acid metabolism are abundantly acetylated as well. 
These findings sparked intense investigation over the past two 
years into the regulatory mechanisms of the acetylation of 
metabolic enzymes, which nicely complements the studies on 
the metabolic regulation by deacetylases in the same period. 
These investigations raised the notion that acetylation may rival 
other common posttranslational modifications in cell regulation 
not only by the number of substrates it modifies, but also the 
variety of regulatory mechanisms it facilitates.
Metabolism refers to the chemical reactions of both synthesis 
(anabolism) and breakdown (catabolism) in living organisms 
and is the essence of life catalyzed by enzymes. The activity of 
metabolic enzymes is controlled by three principle aspects: the 
amount of enzyme, the catalytic activity, and the accessibility 
of substrates. Acetylation has been found to be involved in all 
three aspects of controlling metabolic enzymes. In this review, 
we will discuss the mechanistic insights into how acetylation 
regulates the function of metabolic enzymes. We will focus our 
discussion on mammalian cells and relate the acetylation of 
The activity of metabolic enzymes is controlled by three 
principle levels: the amount of enzyme, the catalytic activ-
ity, and the accessibility of substrates. Reversible lysine 
acetylation is emerging as a major regulatory mechanism 
in metabolism that is involved in all three levels of con-
trolling metabolic enzymes and is altered frequently in 
human diseases. Acetylation rivals other common post-
translational modifications in cell regulation not only in 
the number of substrates it modifies, but also the variety of 
regulatory mechanisms it facilitates.
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intracellular and extracellular processes including cell prolifer­
ation and survival via G protein–coupled receptor signaling. 
Candidate approach studies demonstrated that SPHK1 is acet­
ylated by p300 or cAMP­response element­binding protein 
(CBP) acetyltransferases. Unlike PCK1, acetylation of SPHK1 
is associated with protein stabilization. Mutation of two puta­
tive acetylation­targeted lysine residues blocked SPHK1 ubiq­
uitylation and degradation, leading to the hypothesis that 
acetylation and ubiquitylation may compete for the same sites 
(Yu et al., 2012).
The studies in PCK1 and SPHK1 demonstrate that acety­
lation can either promote or inhibit proteasome­dependent 
degradation by either stimulating interaction with an E3 ubiquitin 
ligase or, perhaps, interfering with the ubiquitylation of lysine 
residues. Based on bioinformatic analyses, a significant fraction 
of acetylation­targeted lysine residues can also be modified by 
ubiquitylation (Weinert et al., 2011). One may speculate that 
a mutually exclusive competition between acetylation and ubiq­
uitylation regulates protein stability. Indeed, recent studies are 
consistent with this model in which acetylation and ubiquitination 
can be mutually exclusive by targeting the same lysine residue 
(e.g., Grönroos et al., 2002).
Acetylation promotes lysosome-dependent 
degradation. In addition to regulating proteasome­dependent 
degradation, acetylation can also regulate the degradation of 
metabolic enzymes by lysosomes. Once thought to function 
primarily in the wholesale breaking down of foreign material 
such as viruses, bacteria, and worn­out cellular organelles 
(micro­ and macroautophagy), lysosomal degradation has been 
recently recognized for the selective degradation of specific 
proteins by a process known as chaperone­mediated autophagy 
(CMA; Mizushima et al., 2008). Pyruvate kinase (PK) catalyzes 
the transfer of phosphate from PEP to ADP, resulting in the for­
mation of pyruvate and ATP. This is an irreversible and crucial 
regulatory step in glycolysis. The human genome encodes two 
distinct PK genes, PKLR and PKM2, that express four PK iso­
forms: L, R, M1, and M2. The L and R isoforms are expressed 
specifically in liver and red blood cells, respectively, from the 
PKLR gene through the use of different promoters. M1 and M2 
are expressed in almost all adult tissues and during embryogen­
esis, respectively, from the PKM2 gene by alternative RNA 
splicing. Notably, PKM2 is highly expressed in a variety of 
tumors (Yamada and Noguchi, 1995; Mazurek et al., 2005). 
The benefit of expressing the PKM2 isoform in rapidly growing 
embryonic and tumorigenic cells is believed to result from 
decreased PK activity, which could lead to accumulation of 
glycolytic metabolites to drive macromolecular biosynthesis 
and cell growth. According to this theory, a regulation that de­
creases or increases PK activity would favor actively dividing 
or quiescent cells, respectively. Acetylation at K305 is stimulated 
by high glucose concentrations and promotes the lysosomal­ 
dependent degradation of PKM2 via CMA. This is supported 
by the findings that K305 acetylation increases PKM2 inter­
action with HSC70, a chaperone that carries target proteins to 
lysosomes for CMA, and PKM2 uptake by lysosomes. Replace­
ment of endogenous wild­type PKM2 with acetylation­mimetic 
K305Q mutant reduced the steady­state level of PKM2, leading 
metabolic enzymes to both normal physiology and pathological 
alteration (Table 1). Investigations of deacetylases, especially 
mitochondrial localized SIRT3, SIRT4, and SIRT5, and to a 
less extent lysine acetyltransferases (KATs), have contributed 
significantly to the physiological significance and genetic support 
of acetylation in regulation of metabolic enzymes. Several 
excellent reviews have recently been written on this topic (Finkel 
et al., 2009; Huang et al., 2010; Albaugh et al., 2011; Chalkiadaki 
and Guarente, 2012).
Regulating the amount of enzyme
Acetylation-mediated proteasomal degradation. 
Crosstalk between different posttranslational modifications that 
occur simultaneously on the same protein provides cells with 
a means to integrate different pathways and coordinate responses 
to different physiological conditions. One good example is 
phosphorylation­targeted protein degradation by the ubiquitin–
proteome system to regulate the amount of intracellar protein 
(Hunter, 2007). Examples are emerging where acetylation plays 
a similar role in directly regulating the amount of metabolic 
enzymes through targeting the substrate to ubiquitylation and 
proteasome­dependent degradation.
Cytosolic phosphoenolpyruvate carboxykinase (PCK1, 
also known as PEPCK1 or PEPCK­C) catalyzes the first com­
mitted, and rate limiting step, of gluconeogenesis by converting 
oxaloacetate into phosphoenolpyruvate (PEP). PCK1 plays an 
important role in controlling cellular and organismal glucose 
homeostasis. Abnormally elevated gluconeogenesis serves as an 
important marker in the evaluation of type II diabetes (Granner and 
O’Brien, 1992). Transcriptional control plays a critical role in 
regulating levels of PCK1, with mRNA levels displaying rapid 
and robust flux in response to changes in energy signals such 
as glucagon and insulin (Yang et al., 2009). What has not been 
adequately appreciated is the control of PCK1 protein stability. 
Several lysine residues were identified as potential acetylation 
targets by the acetylation proteomic studies (Kim et al., 2006; 
Choudhary et al., 2009; Zhao et al., 2010). An early study dem­
onstrated that acetylation of human PEPCK1 is associated with 
its decreased protein stability in cells fed with high glucose 
(Zhao et al., 2010). Subsequently, it was found that PCK1 is 
acetylated by the P300 acetyltransferase (KAT3B) and that 
this acetylation stimulates the interaction between PCK1 and 
UBR5, a HECT domain containing E3 ubiquitin ligase, there­
fore promoting PCK1 ubiquitylation and proteasomal degra­
dation. Conversely, SIRT2 deacetylates and thereby stabilizes 
PCK1. These observations present an interesting example 
where acetylation targets a metabolic enzyme to a specific 
E3 ligase in response to changes in metabolic state (Fig. 1 A; 
Jiang et al., 2011). Ubiquitylation of PCK1 has previously been 
observed in C4 plants where PCK1 catalyzes the same reaction 
and is responsible for the primary fixation of atmospheric CO2 
(Agetsuma et al., 2005). Whether the ubiquitylation of plant 
PCK1 is linked to acetylation and the identity of its E3 ligases 
is unknown.
Sphingosine kinase (SPHK1) is a lipid kinase that cata­
lyzes the phosphorylation of the sphingosine to sphingosine­
1­phosphate (S1P), a signaling molecule involved in both 
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Table 1. Regulation of metabolic enzymes by acetylation
Name Organism Acetylation 
site
Acetylase Deacetylase Effect on  
enzyme
Mechanism Nutrient signal References
Acyl-Coenzyme A  
dehydrogenase,  
long-chain (Acadl)
Mouse K42 Unknown SIRT3 Down- 
regulation













Human Unknown Unknown SIRT1 Down- 
regulation




Human K642 Unknown SIRT3 Down- 
regulation
Active site  
interference
Unknown Hallows et al., 




Human K288 Unknown Unknown Down- 
regulation
Active site  
interference
Stimulated by  
high glucose and  
inhibited by high 
amino acid
Zhao et al., 2010
Carbamoyl phosphate 
synthetase 1(CPS1)
Human Unknown Unknown SIRT5 Down- 
regulation
Unknown Inhibited by starva-
tion, high protein 
diet and calorie 
restriction








Unknown Unknown Up-regulation Unknown Stimulated by high 
fatty acid
Zhao et al., 2010
GAPDH Human K117, K227, 
K251








Ventura et al., 2010
Glutamate dehydrogen-
ase (GDH)
Mouse Unknown Unknown SIRT3 Unknown Unknown Unknown Lombard et al., 
2007







and inhibited by 
glucagon
Zhang et al., 2012
3-hydroxy-3-methylglu-
taryl CoA synthase 2 
(HMGCS2)
Human K310, K447, 
K473








Mouse Unknown Unknown SIRT3 Down- 
regulation
Unknown Inhibited by  
caloric restriction
Someya et al., 2010
Malate dehydrogenase 
(MDH)
Human K185, K301, 
K307, K314
Unknown Unknown Up-regulation Unknown Stimulated by  
high glucose
Zhao et al., 2010
Ornithine carbamoyl-
transferase (OTC)
Human K88 Unknown SIRT3 Down- 
regulation
Active site  
interference
Stimulated by high 
glucose and high 
amino acid
Yu et al., 2009; 





Human K70, K71, 
K594
P300 SIRT2 Down- 
regulation
Promoting  
degradation via  
proteasome
Stimulated by  
high glucose
Jiang et al., 2011
Phosphoglycerate  
mutase 1 (PGAM1)
Human K251, K253, 
K254
Unknown SIRT1 Up-regulation Allowing efficient 
phosphotransfer
Stimulated by  
high glucose
Hallows et al., 
2011a
PK, muscle (PKM2) Human K305 PCAF Unknown Down- 
regulation
Targeting to  
lysosomal  
degradation
Stimulated by  
high glucose
Lv et al., 2011
Succinate dehydrogen-
ase complex,  
subunit A (Sdha)
Mouse K179, K485, 
K498, K538
Unknown SIRT3 Down- 
regulation
Acetylation  
controls the  
substrate entry
Unknown Cimen et al., 2010
Superoxide dismutase 2 
(SOD2)
Human K53, K68 
K89, K122
Unknown SIRT3 Down- 
regulation
Unknown Inhibited by  
nutrient starvation
Qiu et al., 2010; 
Tao et al., 2010; 
Chen et al., 2011
Sphingosine kinase 1 
(SPHK1)
Human K27, K29 P300/CBP Unknown Up-regulation Inhibiting  
degradation via  
proteasome
Unknown Yu et al., 2012
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thereby leading to the inhibition of OTC activity (Yu et al., 
2009) . A simple model explaining these results, as for the 
Lys88­to­Asn (K88N) mutation seen in human OTC deficiency 
(Arranz et al., 2007) or chemical modification of a lysine residue 
in dolphin OTC homologous to K88 of human OTC (Valentini 
et al., 1996), would be that acetylation neutralizes the posi­
tive charge of K88 and reduces the substrate binding to OTC 
(Fig. 2 A). Mitochondrial SIRT3 has subsequently been dem­
onstrated to directly deacetylate OTC at K88 and stimulate 
OTC activity, which is consistent with the observation that 
OTC acetylation is decreased and activity is increased in 
wild­type but not Sirt3/ mice under caloric restriction 
(Hallows et al., 2011b).
Before the acetylation proteomic studies, earlier studies 
had already identified, via the candidate approach, mammalian 
cytoplasmic acetyl­CoA­synthetase (ACSS1, also known as 
AceCS1) and mitochondrial ACSS2 acetylation at specific resi­
dues (K661 in ACSS1 and K642 in ACSS2), and deacetylation 
by cytoplasmic SIRT1 and mitochondrial SIRT3, respectively 
(Hallows et al., 2006; Schwer et al., 2006). ACSS enzymes 
catalyze ATP­dependent ligations of acetate and CoA to produce 
acetyl­CoA. Acetylation of both ACSS1 and ACSS2 negatively 
regulates their activity, which can be reactivated by incubation 
with or overexpression of the respective SIRT deacetylases. 
Both K661 and K642 are highly conserved and located within 
the active site of ACSS’s to function in the ATP­dependent 
adenylation of acetate during the initial catalysis, which suggests 
that acetylation may impair the catalytic activity by neutralizing 
the positive charge of lysine residues and its interaction with 
either ATP or acetate.
Acetylation antagonizes allosteric activation. 
Glycogen phosphorylase (GP) catalyzes the phosphorolytic 
cleavage of glycogen to produce glucose­1­phosphate for glucose­
dependent tissues when serum glucose is low, usually due to 
demand such as during exercise. Defects in glycogen synthesis 
and breakdown in liver, muscle, and other glucose­dependent 
tissues cause glycogen storage diseases (Stegelmeier et al., 1995). 
McArdle’s disease is a prototypical glycogen storage disorder 
that is caused by mutations in muscle GP and characterized 
by pain and fatigue after exercise (Tang et al., 2003; Andreu 
et al., 2007). Extensive investigations have been performed on 
this historic enzyme that lead to the discoveries of two principles 
in enzyme regulation: allosteric regulation by Carl and Gerty 
Cori during the 1930s and 1940s (Cori and Cori, 1936) and re­
versible phosphorylation by Edmond Fischer and Edwin Krebs 
during the 1950s (Fischer and Krebs, 1955). These discoveries 
exemplify how the regulation of enzyme activity is linked to the 
levels of intracellular metabolites such as AMP, and extracel­
lular nutrients such as glucose. When glucose concentration is 
low, glucagon triggers a signal transduction cascade leading to 
the activation of phosphorylase kinase (PhK), which, in turn, 
activates GP by phosphorylating serine­15, leading to increased 
glycogen breakdown and ultimately higher glucose levels. Con­
versely, under high serum glucose conditions, release of insulin 
indirectly activates protein phosphatase­1 (PP1), which dephos­
phorylates serine­15 and converts the active form of GP to its 
unphosphorylated, inactive form, leading to the inhibition of 
to the accumulation of several glycolytic intermediates and 
promotion of cell proliferation and growth (Lv et al., 2011). 
These results not only reveal a novel regulation of PK, but also 
provide one of the first examples of acetylation­targeted protein 
degradation via CMA (Fig. 1 B).
Acetylation affects enzyme  
catalytic activity
Acetylation neutralizes the lysine residue in the 
active site. Lysine has a positively charged ­amino group 
due to protonation at physiological pH. Acetylation of the 
­amino group prevents protonation and thus abolishes the 
positive charge on the lysine side chain. Lysine residues 
are frequently used by enzymes to bind negatively charged 
substrates. Consequently, an acetylated lysine residue has re­
duced affinity to negatively charged groups with which it may 
interact. Acetylation of a lysine residue that participates in an 
enzyme’s catalytic reaction would therefore likely impair the 
enzyme activity. An example of this mechanism is provided by 
the study of ornithine transcarbamylase (OTC), a urea cycle 
enzyme that catalyzes the condensation of ornithine and car­
bamoyl phosphate into citrulline. Ornithine is the deamina­
tion product of arginine, whereas carbamoyl phosphate is the 
condensation product of ammonium generated by amino acid 
deamination and carbon dioxide. Because there is no alternative 
way of urea synthesis, inhibition of any one of the six urea cycle 
enzymes would result in devastating health consequences, 
with OTC deficiency being the most common urea cycle 
disorder (Scaglia et al., 2002). A deficiency of OTC usually 
results in severe central nervous system dysfunction, hyper­
ammonemia, irreversible brain damage, and death in newborn 
infants (Hauser et al., 1990). Acetylation proteomic studies 
have identified several acetylated lysine residues in OTC, 
including the highly conserved Lys88 (K88), which is mu­
tated in OTC­deficient patients and situated in the active site 
involved in substrate binding (Shi et al., 2001). Both the 
treatment of cells with deacetylase inhibitors—nicotinamide 
(NAM) and trichostatin A (TSA)—and substitution to an acetyl­
mimetic glutamine residue (K88Q) were found to decrease the 
affinity for carbamoyl phosphate and the maximum velocity, 
Figure 1. Acetylation regulates the amount of metabolic enzymes. Acety-
lation can regulate the steady-state levels of metabolic enzymes by promot-
ing their degradation through either the ubiquitin–proteasomal system in 
the case of phosphoenolpyruvate carboxykinase (PCK1; A) or CMA in the 
case of PK M2 isoform (PKM2; B). Metabolic enzymes and acetylated 
lysine residues (K) are colored in light green and purple, respectively. 
Active sites are indicated by three red radial dashes.
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increased the catalytic activity (kcat) by almost 50%. The C­terminal 
region of PGAM1, whose removal is associated with loss of 
mutase activity, was previously proposed to act as a so­called 
“dynamic cap” to maintain the enzyme in its active, phosphor­
ylated form by positioning the substrate for catalysis (Walter 
et al., 1999). This result suggests that acetylation of the three 
lysine residues in this region may impact the catalytic activity 
by optimizing the position of the cap to allow efficient phosphate 
transfer from the 3 to the 2 position in glycerate.
Acetylation of lysine residues near the active site has also 
been implicated in the inhibition of manganese superoxide dis­
mutase (SOD2; Qiu et al., 2010), a major antioxidant enzyme 
whose deficiency is associated with various human diseases 
such as idiopathic cardiomyopathy, sporadic motor neuron 
disease, aging, and cancer (Miao and St Clair, 2009). SOD 
scavenges reactive oxygen species (ROS) by catalyzing the 
dismutation of superoxide into oxygen and hydrogen peroxide, 
which is then converted to oxygen and water by catalase. Three 
separate studies have demonstrated that acetylation of SOD2 
inhibits its enzymatic activity, and that oxidative stress stimu­
lates SIRT3 to deacetylate SOD2, leading to SOD2 activation 
and ROS reduction (Qiu et al., 2010; Tao et al., 2010; Chen 
et al., 2011). The precise mechanism by which acetylation 
negatively regulates SOD2 activity, however, remains uncer­
tain, as these three studies each identified a different lysine as 
the major site of acetylation in SOD2.
Acetylation regulates  
substrate accessibility
Acetylation blocks substrate binding to the en-
zyme. Direct immunoblotting of mouse liver mitochondrial 
lysates with anti­acetyl antibody revealed two proteins that are 
noticeably acetylated to a greater degree in Sirt3/ mice than 
glycogen breakdown (Browner and Fletterick, 1992). Acetylation 
was recently found to negatively regulate human GP activity, 
in part by promoting dephosphorylation (Zhang et al., 2012). 
Acetylation of K470 enhances GP’s interaction with the PP1 
substrate–targeting subunit, GL (official name PPP1R3A), and 
thus PP1, thereby promoting GP dephosphorylation and inac­
tivation. GP acetylation is stimulated by insulin and high glu­
cose, and inhibited by glucagon, thereby placing acetylation 
into the network of GP regulation by both nutrients and hormones 
(Fig. 2 B). As much as 50% of GP was acetylated at K470, and 
inhibition of deacetylases resulted in an increase in the ratio of 
acetylated K470 versus unacetylated K470 from roughly 1:1 to 
2:1, which indicates dynamic regulation of K470 acetylation 
in cells. It is pleasantly surprising to see that a new regulatory 
mechanism can still be discovered on such a historically and 
extensively investigated metabolic enzyme, making one won­
dering how much more we can learn from studying these almost 
forgotten metabolic enzymes.
Acetylation causes conformational changes in 
the active site. In fasting and diabetic animals, many cells 
cease carbohydrate utilization and fatty acid synthesis, and switch 
their metabolic programs to fatty acid oxidation (degradation), 
with the concomitant formation of ketone bodies (ketogenesis) in 
the liver that can be transported to other tissues such as brain 
to supply energy. A key enzyme in ketogenesis is mitochondrial 
3­hydroxy­3­methylglutaryl­CoA synthase (HMG­CoA synthase, 
HMGCS2) which, like cytoplasmically localized HMGCS1, 
catalyzes the rate­limiting conversion of acetoacetyl­CoA and 
acetyl­CoA into HMG­CoA, an intermediate in the formation 
of ketone bodies. As expected, the function of HMGCS2 is 
subjected to regulation by multiple signals and mechanisms, 
including transcriptional activation of HMGCS2 gene expres­
sion by glucagon and cAMP (Hegardt, 1999), and competitive 
inhibition at the active site by succinyl­CoA (Quant et al., 1990). 
In a search for the substrates of SIRT3 deacetylase, Shimazu 
et al. (2010) subjected total extracts derived from wild­type and 
Sirt3/ liver mitochondria to mass spectrometric analysis and 
identified HMGCS2 as a substrate of SIRT3. Fasting up­regulated 
Sirt3 levels and reduced HMGCS2 acetylation by 58% in wild­
type mice liver, but had no effect on the hypermethylation of 
HMGCS2 in Sirt3­deficient liver. Deacetylation by SIRT3 or 
mutation of three acetylation sites enhanced HMGCS2 enzy­
matic activity, a finding that is consistent with the decrease of 
­hydroxybutyrate levels during fasting in Sirt3­deficient mice. 
Molecular modeling suggests that acetylation at these three ly­
sine residues could cause a significant conformational change 
around in the acetyl­CoA binding site, thereby affecting the 
positioning of several catalytic residues (Fig. 2 C).
Mammalian phosphoglycerate mutase 1 (PGAM1) cat­
alyzes the reversible reaction of 3­phosphoglycerate (3­PGA) 
to 2­phosphoglycerate (2­PGA) in glycolysis. Acetylation of 
PGAM1 stimulates its enzymatic activity by 30–40%, and is 
decreased by glucose deprivation, presumably by the increase of 
SIRT1 deacetylase, which can deacetylate PGAM1 in vitro 
(Hallows et al., 2011a). Substitutions of a cluster of three adjacent 
lysine residues in the C­terminal region of PGAM1—K251, 
K253, and K254—reduced PGAM1 acetylation by 90% and 
Figure 2. Acetylation regulates the catalytic activity of metabolic 
enzymes. Acetylation can regulate the catalytic activity of metabolic en-
zymes through directly neutralizing the positive charge of lysine residues in 
the active site of OTC (A), recruiting a negative regulator such as phospha-
tase (PPase) to inhibit GP (B), or causing allosteric changes in 3-hydroxy-
3-methylglutaryl-CoA synthase (HMGCS2; C). Enzymes, acetylated lysine 
residues (K), and active sites are labeled as in Fig. 1. S, substrate.
JCB • VOLUME 198 • NUMBER 2 • 2012 160
also participates in other cellular processes including transcrip­
tional regulation, DNA repair, and telomere maintenance in the 
nucleus (Zheng et al., 2003). Translocation of GAPDH into the 
nucleus can be influenced by cellular growth conditions such 
as cell cycle and apoptosis (Tristan et al., 2011). Three different 
types of posttranslational modifications, O­GlcNAcylation 
(Park et al., 2009), S­nitrosylation (Hara et al., 2005), and 
acetylation (Ventura et al., 2010), have been linked to GAPDH 
nuclear translocation. Overexpression of PCAF acetyltransfer­
ase (p300/CBP­associated factor, KAT2B), which binds to and 
acetylates GAPDH, and treatment of cells with a deacetylase 
inhibitor, TSA, increases nuclear accumulation of ectopically 
expressed GAPDH (Ventura et al., 2010). Substitution of two 
putative PCAF acetylation residues with arginine in GAPDH, 
but not the acetyl­mimetic glutamine, blocked TSA­mediated 
nuclear accumulation in GAPDH, suggesting that acetylation 
promotes GAPDH nuclear accumulation (Fig. 3 B). It remains 
to be elucidated how acetylation promotes GAPDH nuclear 
translocation, whether by changing the conformation to inhibit 
tetramer formation like O­GlcNAcylation (Park et al., 2009), 
or by promoting its binding to and getting a ride with nuclear­ 
localized proteins such as SIAH1 (Sen et al., 2008).
Acetylation blocks the binding of metabolites. 
In addition to impacting substrate binding, acetylation has 
also been found to affect the binding of allosteric regulating 
metabolites. In a study aimed at unraveling the paradoxical 
roles of mitochondrial­enriched SIRT3 in fasting and calorie 
restriction, Lu et al., (2011) investigated the role of acetyla­
tion in both protecting against redox stress and exacerbating 
redox­dependent toxicity of the pain relief agent acetamino­
phen (e.g., Tylenol). Acetaminophen causes a potentially fatal 
hepatic necrosis when taken in overdose, resulting from the 
production by cytochrome P450 enzymes of a reactive metab­
olite, N­acetyl­p­benzoquinone imine (NAPQI), that binds to 
hepatic cysteine residues as well as (unmodified) lysine resi­
dues (James et al., 2003). Protein acetylation, like N­acetyl­
cysteine therapy, may block the NAPQI binding. Conversely, 
deacetylation, such as loss of function in SIRT3, may exacer­
bate NAPQI binding and acetaminophen hepatotoxicity. Using 
two­dimensional gel and mass spectrometric of differentially 
acetylated spots, Lu et al. (2011) identified 17 liver mitochon­
drial proteins whose acetylation is enhanced in Sirt3/ mice, 
including aldehyde dehydrogenase (ALDH2). ALDH2 is a key 
enzyme in alcohol metabolism because of its high affinity for 
its substrate acetaldehyde, which it reduces to acetate. ALDH2 
is a known target of NAPQI, and is inactivated by it. Substitu­
tion of a single lysine residue, K377, with an acetyl­mimetic 
glutamine nearly completely abolished NAPQI binding (Lu 
et al., 2011), which demonstrates the importance of acetylation 
at this lysine residue in antagonizing the binding of NAPQI. 
This provides an intriguing example in which acetylation can 
affect enzyme function by interfering with the binding of allo­
sterically regulating molecules.
Major questions in the field
In addition to the examples discussed above, there are sev­
eral metabolic enzymes whose acetylation has been firmly 
in wild­type mice (Cimen et al., 2010). These two bands were 
identified by mass spectrometry to be succinate dehydrogenase 
subunit A (SDHA) and glutamate dehydrogenase (GDH). SDH 
is a unique enzyme that participates in both the TCA cycle, to 
catalyze the oxidation of succinate to fumarate, and in oxidative 
phosphorylation as a component of the electron transport chain 
(complex II), where it catalyzes the reduction of ubiquinone to 
ubiquinol. Human SDH is composed of four subunits encoded 
by four distinct genes, SDHA, SDHB, SDHC, and SDHD, and 
is activated by a newly discovered assembly factor, SDHAF2 
(also known as SDH5). In addition to its critical physiologi­
cal function, SDH regulation also bears important pathologi­
cal significance, as mutations in all five SDH genes have been 
linked to tumor development (Bardella et al., 2011). Acetyla­
tion of SDHA through chemical inhibition of cellular SIRTs 
and deacetylation of SDHA by the overexpression of SIRT3 
resulted in decreased and increased complex II activity, respec­
tively, which indicates an inhibitory role of acetylation toward 
SDHA (Cimen et al., 2010). Four lysine residues were iden­
tified by mass spectrometry to be acetylated. They are highly 
conserved during the evolution from bacteria to human, and are 
located on the hydrophilic surface of SDHA, which suggests 
that acetylation at these sites may hinder the entry of substrate 
into the active site (Fig. 3 A).
Acetylation modulates enzyme subcellular 
localization. Besides directly regulating the accessibility of 
substrate, acetylation can indirectly regulate substrate acces­
sibility by affecting subcellular localization of the metabolic 
enzyme. One such an example is acetylation­mediated nuclear 
translocation of glyceraldehyde­3­phosphate dehydrogenase 
(GAPDH; Ventura et al., 2010). GAPDH, long considered to be 
a housekeeping gene that is widely used as a protein loading 
control because of its relatively constant levels, catalyzes the 
NAD+­dependent conversion of glyceraldehyde­3­phosphate 
(G3P) to 1,3 bisphosphoglycerate (1,3BPG). Besides its conven­
tional role in catalyzing glycolysis within the cytoplasm, GAPDH 
Figure 3. Acetylation regulates the substrate accessibility to metabolic 
enzymes. (A) Acetylation can regulate the substrate accessibility to met-
abolic enzymes by modifying the conserved lysine residues located on 
the hydrophilic surface of SDHA to hinder the entry of substrate (S) into 
the active site. (B) Acetylation can also alter the access of cytoplasmic 
substrates to GAPDH by promoting nuclear accumulation of GAPDH. 
Enzymes, acetylated lysine residues (K), and active sites are labeled as in 
Fig. 1. N, nucleus; C, cytoplasm.
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many metabolic enzymes, immediately implicating both modi­
fications in metabolic regulation. Substitution of a lysine with 
a glutamine would effectively eliminate all these modifications 
on lysine, and therefore potentially create a complicated net­
work of unforeseen metabolic consequences. An effective way 
to address this issue is to use anti­acetylation site antibodies for 
functional studies, which can also help to determine the in vivo 
change of acetylation on a given site in response to a change in 
cellular conditions.
What fraction of a given metabolic enzyme is 
acetylated? In most studies thus far on the acetylation regu­
lation of metabolic enzymes, there is a lack of quantification of 
what fraction is acetylated under specific physiological condi­
tions. Acetylation of a small fraction of steady­state proteins 
may be sufficient to regulate enzymatic function if acetylation 
promotes enzyme degradation. Similarly, a substoichiometric 
acetylation may also play a significant role in physiological 
regulation if acetylation results in a gain of function or alters 
the subcellular localization. Quantification of acetylation is, 
however, critically important for many metabolic enzymes, 
as acetylation often targets evolutionary conserved and func­
tionally important lysine residues (Weinert et al., 2011), and 
is therefore expected to cause loss of function changes. For 
example, inhibitory acetylation of 10% of a given enzyme would 
leave cells with 90% enzyme activity, a change that is unlikely 
to have a significant impact on cell metabolism. In several 
studies where acetylation on a specific site or an enzyme has 
been determined, however, it appears that a significant frac­
tion of the enzyme is acetylated. For example, 27% and 67% 
of ectopically expressed MDH2 was acetylated in the ab­
sence or presence of deacetylase inhibitors, respectively, as 
determined by Fourier transform ion cyclotron resonance 
(FTICR) mass spectrometry (Zhao et al., 2010). Using a different 
established and linked to the cellular 
response to specific nutrient and growth 
conditions (Table 1). For example, the 
activity of mitochondrial isocitrate dehy­
drogenase 2 (IDH2), a TCA enzyme that 
catalyzes the decarboxylation of isocitrate 
to ­ketoglutarate, is inhibited by acetyla­
tion and is stimulated by SIRT3­mediated 
deacetylation in response to caloric restric­
tion, leading to increased production of 
NAPDH and reduced oxidative damage 
(Someya et al., 2010). The acetylation site 
for IDH2 has not been determined, and 
the mechanism of acetylation regulation of 
IDH2 therefore remains to be elucidated. 
Long chain acyl coenzyme A dehydroge­
nase 2 (ACADC, also known as LCAD) 
catalyzes the initial step in each cycle of 
fatty acid ­oxidation in the mitochondria, 
and is acetylated in fed mice but deacety­
lated by SIRT3 during fasting (Hirschey 
et al., 2010). One specific lysine residue, 
K42, was identified to be its major acety­
lation site, which, when mutated, signifi­
cantly increased the activity of ACADC. How acetylation at 
K42 mechanistically impairs the activity of ACADC is pres­
ently unknown, as the location of K42 does not suggest an obvi­
ous impact from its acetylation.
We can anticipate many new findings on the regulation of 
metabolic enzymes by acetylation, including novel mechanistic 
insights, to be made in the near future. Many outstanding and 
critical issues have emerged. Among them are four that directly 
relate to the regulation of metabolic enzymes and metabolism, 
and bear broad implications for the acetylation regulation of 
proteins in other cellular processes (see Text Box).
How to functionally validate the acetylation 
identified by proteomics? More than 2,000 putative acet­
ylated proteins have already been identified by just a few pro­
teomic studies, and there are almost certainly more that have 
yet to be identified. Functional validation of these studies is 
rapidly becoming a critical issue. A commonly used method 
to study the function of a putative acetylation site is to deter­
mine the effect of substituting a given lysine with glutamine. 
Although both acetyl­lysine and glutamine may be most simi­
lar among all amino acids, and there are many good examples 
where the K­to­Q mutation mimics acetylation, glutamine is 
structurally different from N­acetyl­lysine because of a sig­
nificantly shorter carbon chain and the carbonyl group of the 
amide being at a different position. Of larger concern is that ly­
sine is known to be modified by many additional types of post­
translational modifications such as ubiquitylation, methylation, 
and hydroxylation. In particularly, two new types of lysine 
modifications, succinylation and malonylation, were recently 
described, and SIRT5 has been identified to be the enzyme that 
removes both modifying groups (desuccinylase and demola­
nylase; Du et al., 2011; Peng et al., 2011). Preliminary identi­
fication of succinylation and malonylation substrates includes 
Major questions in the field
1. How to functionally validate the acetylation identified by proteomics?
More than 2,000 putative acetylated proteins have already been identified by just a few 
proteomic studies, and there are almost certainly more that have yet to be discovered. 
Generation and use of anti-acetylation site antibodies remains the major technique to vali-
date and elucidate the function of acetylation on a given lysine residue.
2. What fraction of a given metabolic enzyme is acetylated?
In most studies thus far on the regulation of metabolic enzymes by acetylation, there is a 
lack of quantification of what fraction is acetylated under specific physiological conditions. 
The rapid progress of quantitative mass spectrometry is significantly facilitating the quanti-
fication of acetylation, and may soon become a standard in the field.
3. How do a few modifying enzymes control so many substrates?
More than 2,000 proteins have been identified by proteomic studies to be potentially acet-
ylated, but there are only 22 acetyltransferases and 18 deacetylases that have been identi-
fied in human cells. Three different mechanisms can be envisioned on how so few modifying 
enzymes control the acetylation of so many substrates: the existence of a novel class of 
acetyltransferases and/or deacetylases, the existence of a novel class of substrate recep-
tors, and nonenzymatic covalent conjugation of an acetyl group to a lysine residue.
4. How does acetylation affect many metabolic enzymes in a coordinated manner?
Nearly all of the enzymes involved in glycolysis, the TCA cycle, the urea cycle, fatty acid 
oxidation, and nitrogen metabolism are potentially acetylated. A unique feature of acetyla-
tion is that the acetyl group donor for all acetyltransferases, Ac-CoA, and the electron ac-
ceptor (or coenzyme) of SIRT family of deacetylases, NAD+, are both key intermediate 
metabolites produced and consumed by many metabolic reactions. This feature suggests 
that acetylation of multiple enzymes on a pathway could be coordinated in part by the 
global change in the levels of intracellular Ac-CoA and NAD+.
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substrate binding or enzyme activity. Therefore, the limited 
numbers of catalytic subunits of the modifying enzymes may 
be assembled with binding partners into a large family that can 
meet the need for specificity in vivo. Lastly, and more radically, 
the covalent conjugation of an acetyl group to a lysine residue, 
or removal of an acetyl group from acetyl­lysine, could occur 
nonenzymatically. One such precedent is protein succination, 
in which a mitochondrial metabolic intermediate, fumarate, reacts 
spontaneously with cysteine sulfhydryl group in a Michael 
reaction (nucleophilic addition of a carbanion) to form a stable 
S­(2­succinyl) cysteine (Alderson et al., 2006).
How does acetylation affect many metabolic 
enzymes in a coordinated manner? Many metabolic 
enzymes were identified by the acetylation proteomic studies. 
This is particularly obvious for enzymes involved in glycoly­
sis, TCA, urea cycle, fatty acid oxidation, and nitrogen metab­
olism, where most enzymes are potentially acetylated. Such 
far­reaching regulation of a specific cellular process, metabo­
lism, by one specific type of modification is reminiscent of the 
regulation of signal transduction by phosphorylation, and the 
cell cycle by ubiquitylation. It raises the question as to how 
cells coordinate the acetylation of multiple enzymes involved 
in a single pathway. This question becomes even more pro­
found when considering two additional issues: only a few 
acetyltransferases and deacetylases are known to be involved, 
and most metabolic pathways are not linear; rather, they form 
a network with many branches from each pathway sharing 
common intermediates.
The answer may come in part from a unique feature of 
acetylation: the fact that the acetyl group donor for all acetyl­
transferases, Ac­CoA, and the electron acceptor (or coenzyme) 
of SIRT family of deacetylases, NAD+, are both key inter­
mediate metabolites produced and consumed by many meta­
bolic reactions. Support for this notion comes from a study 
showing that nuclear histone acetylation in mammalian cells 
is reduced by the knocking down of ATP­citrate lyase (ACL), 
the enzyme that converts glucose­derived citrate into acetyl­
CoA (Wellen et al., 2009), which suggests that acetylation of 
substrate proteins can be influenced by the global change in 
the levels of intracellular Ac­CoA. One implication of this 
finding would be to allow cells to rapidly sense the change of 
concentration of acetyl­CoA and NAD+ and to globally influ­
ence the acetylation level and activity of metabolic enzymes 
in response.
Lysine acetylation has emerged as a major posttransla­
tional modification in the regulation of metabolism and many 
other similar cellular processes. Given the wide range of regu­
latory mechanisms it impacts and the high degree of evolu­
tionary conservation, acetylation regulation of metabolism seems 
poised to only grow in significance as we continue to discover 
its functions and mechanisms.
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technique, known as isobaric tags for relative and absolute 
quantification (iTRAQ), it was determined that as much as 50% 
of GP was acetylated at K470 (Zhang et al., 2012); and 44% 
and 47% of enoyl­CoA, hydratase/3­hydroxyacyl­CoA dehy­
drogenase (EHHADH), an essential enzyme that metabolizes 
fatty acids to produce actyl CoA and release energy, is acety­
lated at K171 and K346, respectively (Zhao et al., 2010). Both 
FTICR and iTRAQ techniques have some obvious limitations: 
they have low throughput, and are labor intensive and costly. 
Given the rapid progress of quantitative mass spectrometry, 
such as stable isotope labeling by amino acids (SILAC) or label­
free, high­throughput quantification, one can expect that deter­
mining the quantification of acetylation will soon become a 
standard in the field.
How do a few modifying enzymes control so 
many substrates? The identification of such a large num­
ber of acetylated proteins by proteomic studies, already >2,000, 
raises an acute conundrum: how do so few enzymes, 22 acet­
yltransferases (KATs; Allis et al., 2007) and 18 deacetylases 
(11 HDACs [Riccio, 2010] and 7 SIRTs [Schwer and Verdin, 
2008]) in human cells, control the acetylation of so many sub­
strates? Making the puzzle even more challenging is the fact 
that only three (SIRT1, ­2, and ­3) have clearly demonstrated 
deacetylase activity. Distinct from the others, SIRT5 has been 
found to be a lysine desuccinylase and demalonylase (Du 
et al., 2011; Peng et al., 2011). Phylogenetic analysis suggests 
that the remaining three (SIRT4, ­6, and ­7) may have novel 
enzymatic activity in removing different acyl modifications 
(Hirschey, 2011). For perspective, more than 500 protein ki­
nases and an equally large numbers of phosphatases (the exact 
number is less certain because of the complex combinations of 
different subunits), and more than an estimated 700 E3 ubiq­
uitin ligases with more than 100 deubiquitinases in human 
cells are found to control reversible protein phosphorylation 
and ubiquitylation, respectively. There are no obvious clues, 
much less answers, to how so few modifying enzymes reg­
ulate so many substrates. Three different mechanisms can 
be envisioned though. First, there may exist a novel class of 
acetyltransferases and/or deacetylases yet to be discovered. 
A reminder of this scenario is the history of E3 ubiquitin ligase 
research, where HECT domain–containing proteins (homolo­
gous to E6­AP carboxyl terminus) were the major type of E3 
ligases until the discovery of RING­type E3 ligases. Human 
cells contain 28 HECT E3 ligases, but more than 300 RING 
finger proteins and an estimated 400 additional RING­type E3 
ligases were assembled by the Cullin family proteins through 
binding, in trans, with a small RING finger protein. Second, 
an individual acetyltransferase and deacetylase could control 
multiple substrates. This certainly is happening in the cell to 
some extent. Analyses of acetylation levels of several meta­
bolic enzymes in mouse organs deficient for individual SIRTs, 
such as SIRT3 (e.g., Table 1), or in vitro deacetylation assays, 
can be seen as consistent with this model. However, this model 
poses a serious question: how can acetylation of different 
proteins be specifically regulated under different physiological 
conditions? One possibility is that each acetyltransferase or 
deacetylase may have additional binding partners that regulate 
163Mechanistic insights of acetylation • Xiong and Guan
Grönroos, E., U. Hellman, C.H. Heldin, and J. Ericsson. 2002. Control of Smad7 
stability by competition between acetylation and ubiquitination. Mol. 
Cell. 10:483–493. http://dx.doi.org/10.1016/S1097­2765(02)00639­1
Guan, K.L., and Y. Xiong. 2011. Regulation of intermediary metabolism by 
protein acetylation. Trends Biochem. Sci. 36:108–116. http://dx.doi.org/ 
10.1016/j.tibs.2010.09.003
Hallows, W.C., S. Lee, and J.M. Denu. 2006. Sirtuins deacetylate and acti­
vate mammalian acetyl­CoA synthetases. Proc. Natl. Acad. Sci. USA. 
103:10230–10235. http://dx.doi.org/10.1073/pnas.0604392103
Hallows, W.C., W. Yu, and J.M. Denu. 2012a. Regulation of glycolytic enzyme 
phosphoglycerate mutase­1 by Sirt1 protein­mediated deacetylation. J. 
Biol. Chem. 287:3850–3858. http://dx.doi.org/10.1074/jbc.M111.317404
Hallows, W.C., W. Yu, B.C. Smith, M.K. Devries, J.J. Ellinger, S. Someya, 
M.R. Shortreed, T. Prolla, J.L. Markley, L.M. Smith, et al. 2011b. 
Sirt3 promotes the urea cycle and fatty acid oxidation during dietary 
restriction. Mol. Cell. 41:139–149. (published erratum appears in Mol. 
Cell. 2011. 41:493) http://dx.doi.org/10.1016/j.molcel.2011.01.002
Hara, M.R., N. Agrawal, S.F. Kim, M.B. Cascio, M. Fujimuro, Y. Ozeki, 
M. Takahashi, J.H. Cheah, S.K. Tankou, L.D. Hester, et al. 2005. 
S­nitrosylated GAPDH initiates apoptotic cell death by nuclear trans­
location following Siah1 binding. Nat. Cell Biol. 7:665–674. http://
dx.doi.org/10.1038/ncb1268
Hauser, E.R., J.E. Finkelstein, D. Valle, and S.W. Brusilow. 1990. Allopurinol­
induced orotidinuria. A test for mutations at the ornithine carbam­
oyltransferase locus in women. N. Engl. J. Med. 322:1641–1645. 
http://dx.doi.org/10.1056/NEJM199006073222305
Hegardt, F.G. 1999. Mitochondrial 3­hydroxy­3­methylglutaryl­CoA synthase: 
a control enzyme in ketogenesis. Biochem. J. 338:569–582. http://dx.doi 
.org/10.1042/0264­6021:3380569
Hirschey, M.D. 2011. Old enzymes, new tricks: sirtuins are NAD(+)­dependent 
de­acylases. Cell Metab. 14:718–719. http://dx.doi.org/10.1016/j.cmet 
.2011.10.006
Hirschey, M.D., T. Shimazu, E. Goetzman, E. Jing, B. Schwer, D.B. Lombard, 
C.A. Grueter, C. Harris, S. Biddinger, O.R. Ilkayeva, et al. 2010. SIRT3 
regulates mitochondrial fatty­acid oxidation by reversible enzyme deacety­
lation. Nature. 464:121–125. http://dx.doi.org/10.1038/nature08778
Huang, J.Y., M.D. Hirschey, T. Shimazu, L. Ho, and E. Verdin. 2010. 
Mitochondrial sirtuins. Biochim. Biophys. Acta. 1804:1645–1651.
Hunter, T. 2007. The age of crosstalk: phosphorylation, ubiquitination, and beyond. 
Mol. Cell. 28:730–738. http://dx.doi.org/10.1016/j.molcel.2007.11.019
James, L.P., P.R. Mayeux, and J.A. Hinson. 2003. Acetaminophen­induced 
hepatotoxicity. Drug Metab. Dispos. 31:1499–1506. http://dx.doi.org/ 
10.1124/dmd.31.12.1499
Jiang, W., S. Wang, M. Xiao, Y. Lin, L. Zhou, Q. Lei, Y. Xiong, K.L. Guan, 
and S. Zhao. 2011. Acetylation regulates gluconeogenesis by promoting 
PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell. 
43:33–44. http://dx.doi.org/10.1016/j.molcel.2011.04.028
Kim, S.C., R. Sprung, Y. Chen, Y. Xu, H. Ball, J. Pei, T. Cheng, Y. Kho, H. 
Xiao, L. Xiao, et al. 2006. Substrate and functional diversity of lysine 
acetylation revealed by a proteomics survey. Mol. Cell. 23:607–618. 
http://dx.doi.org/10.1016/j.molcel.2006.06.026
Lombard, D.B., F.W. Alt, H.L. Cheng, J. Bunkenborg, R.S. Streeper, R. 
Mostoslavsky, J. Kim, G. Yancopoulos, D. Valenzuela, A. Murphy, 
et al. 2007. Mammalian Sir2 homolog SIRT3 regulates global mitochon­
drial lysine acetylation. Mol. Cell. Biol. 27:8807–8814. http://dx.doi.org/ 
10.1128/MCB.01636­07
Lu, Z., M. Bourdi, J.H. Li, A.M. Aponte, Y. Chen, D.B. Lombard, M. Gucek, 
L.R. Pohl, and M.N. Sack. 2011. SIRT3­dependent deacetylation exac­
erbates acetaminophen hepatotoxicity. EMBO Rep. 12:840–846. http://
dx.doi.org/10.1038/embor.2011.121
Lv, L., D. Li, D. Zhao, R.T. Lin, Y. Chu, H. Zhang, Z. Zha, Y. Liu, Z. Li, 
Y. Xu, et al. 2011. Acetylation targets the M2 isoform of pyruvate 
kinase for degradation through chaperone­mediated autophagy and 
promotes tumor growth. Mol. Cell. 42:719–730. http://dx.doi.org/10 
.1016/j.molcel.2011.04.025
Mazurek, S., C.B. Boschek, F. Hugo, and E. Eigenbrodt. 2005. Pyruvate kinase 
type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 
15:300–308. http://dx.doi.org/10.1016/j.semcancer.2005.04.009
Miao, L., and D.K. St Clair. 2009. Regulation of superoxide dismutase genes: 
implications in disease. Free Radic. Biol. Med. 47:344–356. http://dx.doi 
.org/10.1016/j.freeradbiomed.2009.05.018
Mizushima, N., B. Levine, A.M. Cuervo, and D.J. Klionsky. 2008. Autophagy 
fights disease through cellular self­digestion. Nature. 451:1069–1075. 
http://dx.doi.org/10.1038/nature06639
Nakagawa, T., D.J. Lomb, M.C. Haigis, and L. Guarente. 2009. SIRT5 
Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea 
cycle. Cell. 137:560–570. http://dx.doi.org/10.1016/j.cell.2009.02.026
Submitted: 10 February 2012
Accepted: 14 June 2012
References
Agetsuma, M., T. Furumoto, S. Yanagisawa, and K. Izui. 2005. The ubiquitin­
proteasome pathway is involved in rapid degradation of phosphoenol­
pyruvate carboxylase kinase for C4 photosynthesis. Plant Cell Physiol. 
46:389–398. http://dx.doi.org/10.1093/pcp/pci043
Albaugh, B.N., K.M. Arnold, and J.M. Denu. 2011. KAT(ching) metabolism 
by the tail: insight into the links between lysine acetyltransferases and 
metabolism. ChemBioChem. 12:290–298. http://dx.doi.org/10.1002/ 
cbic.201000438
Alderson, N.L., Y. Wang, M. Blatnik, N. Frizzell, M.D. Walla, T.J. Lyons, 
N. Alt, J.A. Carson, R. Nagai, S.R. Thorpe, and J.W. Baynes. 2006. 
S­(2­Succinyl)cysteine: a novel chemical modification of tissue pro­
teins by a Krebs cycle intermediate. Arch. Biochem. Biophys. 450:1–8. 
http://dx.doi.org/10.1016/j.abb.2006.03.005
Allfrey, V.G., R. Faulkner, and A.E. Mirsky. 1964. Acetylation and methyla­
tion of histones and their possible role in the regulation of RNA syn­
thesis. Proc. Natl. Acad. Sci. USA. 51:786–794. http://dx.doi.org/10 
.1073/pnas.51.5.786
Allfrey, V.G., B.G. Pogo, V.C. Littau, E.L. Gershey, and A.E. Mirsky. 1968. 
Histone acetylation in insect chromosomes. Science. 159:314–316. 
http://dx.doi.org/10.1126/science.159.3812.314
Allis, C.D., S.L. Berger, J. Cote, S. Dent, T. Jenuwien, T. Kouzarides, L. Pillus, 
D. Reinberg, Y. Shi, R. Shiekhattar, et al. 2007. New nomenclature for 
chromatin­modifying enzymes. Cell. 131:633–636. http://dx.doi.org/10 
.1016/j.cell.2007.10.039
Andreu, A.L., G. Nogales­Gadea, D. Cassandrini, J. Arenas, and C. Bruno. 2007. 
McArdle disease: molecular genetic update. Acta Myol. 26:53–57.
Arranz, J.A., E. Riudor, C. Marco­Marín, and V. Rubio. 2007. Estimation of the 
total number of disease­causing mutations in ornithine transcarbamylase 
(OTC) deficiency. Value of the OTC structure in predicting a mutation 
pathogenic potential. J. Inherit. Metab. Dis. 30:217–226. http://dx.doi 
.org/10.1007/s10545­007­0429­x
Bardella, C., P.J. Pollard, and I. Tomlinson. 2011. SDH mutations in cancer. 
Biochim. Biophys. Acta. 1807:1432–1443. http://dx.doi.org/10.1016/j 
.bbabio.2011.07.003
Browner, M.F., and R.J. Fletterick. 1992. Phosphorylase: a biological trans­
ducer. Trends Biochem. Sci. 17:66–71. http://dx.doi.org/10.1016/0968­ 
0004(92)90504­3
Chalkiadaki, A., and L. Guarente. 2012. Sirtuins mediate mammalian meta­
bolic responses to nutrient availability. Nat Rev Endocrinol. 8:287–296. 
http://dx.doi.org/10.1038/nrendo.2011.225
Chen, Y., J. Zhang, Y. Lin, Q. Lei, K.L. Guan, S. Zhao, and Y. Xiong. 2011. 
Tumour suppressor SIRT3 deacetylates and activates manganese super­
oxide dismutase to scavenge ROS. EMBO Rep. 12:534–541. http://dx.doi 
.org/10.1038/embor.2011.65
Choudhary, C., and M. Mann. 2010. Decoding signalling networks by mass 
spectrometry­based proteomics. Nat. Rev. Mol. Cell Biol. 11:427–439. 
http://dx.doi.org/10.1038/nrm2900
Choudhary, C., C. Kumar, F. Gnad, M.L. Nielsen, M. Rehman, T.C. Walther, 
J.V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein com­
plexes and co­regulates major cellular functions. Science. 325:834–840. 
http://dx.doi.org/10.1126/science.1175371
Cimen, H., M.J. Han, Y. Yang, Q. Tong, H. Koc, and E.C. Koc. 2010. 
Regulation of succinate dehydrogenase activity by SIRT3 in mam­
malian mitochondria. Biochemistry. 49:304–311. http://dx.doi.org/ 
10.1021/bi901627u
Cori, C.F., and G.T. Cori. 1936. Mechanism of formation of hexosemonophos­
phate in muscle and isolation of a new phosphate ester. Exp. Biol. Med. 
34:702–705.
Du, J., Y. Zhou, X. Su, J.J. Yu, S. Khan, H. Jiang, J. Kim, J. Woo, J.H. Kim, 
B.H. Choi, et al. 2011. Sirt5 is a NAD­dependent protein lysine de­
malonylase and desuccinylase. Science. 334:806–809. http://dx.doi.org/ 
10.1126/science.1207861
Finkel, T., C.X. Deng, and R. Mostoslavsky. 2009. Recent progress in the biol­
ogy and physiology of sirtuins. Nature. 460:587–591. http://dx.doi.org/ 
10.1038/nature08197
Fischer, E.H., and E.G. Krebs. 1955. Conversion of phosphorylase b to phos­
phorylase a in muscle extracts. J. Biol. Chem. 216:121–132.
Granner, D.K., and R.M. O’Brien. 1992. Molecular physiology and genetics of 
NIDDM. Importance of metabolic staging. Diabetes Care. 15:369–395. 
http://dx.doi.org/10.2337/diacare.15.3.369
JCB • VOLUME 198 • NUMBER 2 • 2012 164
Park, J., D. Han, K. Kim, Y. Kang, and Y. Kim. 2009. O­GlcNAcylation dis­
rupts glyceraldehyde­3­phosphate dehydrogenase homo­tetramer for­
mation and mediates its nuclear translocation. Biochim. Biophys. Acta. 
1794:254–262.
Peng, C., Z. Lu, Z. Xie, Z. Cheng, Y. Chen, M. Tan, H. Luo, Y. Zhang, W. He, K. 
Yang, et al. 2011. The first identification of lysine malonylation substrates 
and its regulatory enzyme. Mol. Cell. Proteomics. 10:M111:012658. 
http://dx.doi.org/10.1074/mcp.M111.012
Phillips, D.M. 1963. The presence of acetyl groups of histones. Biochem. J. 
87:258–263.
Qiu, X., K. Brown, M.D. Hirschey, E. Verdin, and D. Chen. 2010. Calorie re­
striction reduces oxidative stress by SIRT3­mediated SOD2 activation. 
Cell Metab. 12:662–667. http://dx.doi.org/10.1016/j.cmet.2010.11.015
Quant, P.A., P.K. Tubbs, and M.D. Brand. 1990. Glucagon activates mitochon­
drial 3­hydroxy­3­methylglutaryl­CoA synthase in vivo by decreasing 
the extent of succinylation of the enzyme. Eur. J. Biochem. 187:169–174. 
http://dx.doi.org/10.1111/j.1432­1033.1990.tb15291.x
Riccio, A. 2010. New endogenous regulators of class I histone deacetylases. Sci. 
Signal. 3:pe1. http://dx.doi.org/10.1126/scisignal.3103pe1
Scaglia, F., Q. Zheng, W.E. O’Brien, J. Henry, J. Rosenberger, P. Reeds, and 
B. Lee. 2002. An integrated approach to the diagnosis and prospective 
management of partial ornithine transcarbamylase deficiency. Pediatrics. 
109:150–152. http://dx.doi.org/10.1542/peds.109.1.150
Schwer, B., and E. Verdin. 2008. Conserved metabolic regulatory functions 
of sirtuins. Cell Metab. 7:104–112. http://dx.doi.org/10.1016/j.cmet 
.2007.11.006
Schwer, B., J. Bunkenborg, R.O. Verdin, J.S. Andersen, and E. Verdin. 2006. 
Reversible lysine acetylation controls the activity of the mitochondrial 
enzyme acetyl­CoA synthetase 2. Proc. Natl. Acad. Sci. USA. 103:10224–
10229. http://dx.doi.org/10.1073/pnas.0603968103
Sen, N., M.R. Hara, M.D. Kornberg, M.B. Cascio, B.I. Bae, N. Shahani, B. 
Thomas, T.M. Dawson, V.L. Dawson, S.H. Snyder, and A. Sawa. 
2008. Nitric oxide­induced nuclear GAPDH activates p300/CBP and 
mediates apoptosis. Nat. Cell Biol. 10:866–873. http://dx.doi.org/10 
.1038/ncb1747
Shi, D., H. Morizono, X. Yu, L. Tong, N.M. Allewell, and M. Tuchman. 2001. 
Human ornithine transcarbamylase: crystallographic insights into sub­
strate recognition and conformational changes. Biochem. J. 354:501–
509. http://dx.doi.org/10.1042/0264­6021:3540501
Shimazu, T., M.D. Hirschey, L. Hua, K.E. Dittenhafer­Reed, B. Schwer, D.B. 
Lombard, Y. Li, J. Bunkenborg, F.W. Alt, J.M. Denu, et al. 2010. SIRT3 
deacetylates mitochondrial 3­hydroxy­3­methylglutaryl CoA synthase 2 
and regulates ketone body production. Cell Metab. 12:654–661. http://
dx.doi.org/10.1016/j.cmet.2010.11.003
Someya, S., W. Yu, W.C. Hallows, J. Xu, J.M. Vann, C. Leeuwenburgh, 
M. Tanokura, J.M. Denu, and T.A. Prolla. 2010. Sirt3 mediates re­
duction of oxidative damage and prevention of age­related hearing 
loss under caloric restriction. Cell. 143:802–812. http://dx.doi.org/ 
10.1016/j.cell.2010.10.002
Stegelmeier, B.L., R.J. Molyneux, A.D. Elbein, and L.F. James. 1995. The le­
sions of locoweed (Astragalus mollissimus), swainsonine, and castano­
spermine in rats. Vet. Pathol. 32:289–298. http://dx.doi.org/10.1177/ 
030098589503200311
Tang, N.L., J. Hui, E. Young, V. Worthington, K.F. To, K.L. Cheung, C.K. Li, 
and T.F. Fok. 2003. A novel mutation (G233D) in the glycogen phos­
phorylase gene in a patient with hepatic glycogen storage disease and 
residual enzyme activity. Mol. Genet. Metab. 79:142–145. http://dx.doi 
.org/10.1016/S1096­7192(03)00068­4
Tao, R., M.C. Coleman, J.D. Pennington, O. Ozden, S.H. Park, H. Jiang, H.S. 
Kim, C.R. Flynn, S. Hill, W. Hayes McDonald, et al. 2010. Sirt3­
 mediated deacetylation of evolutionarily conserved lysine 122 regulates 
MnSOD activity in response to stress. Mol. Cell. 40:893–904. http://
dx.doi.org/10.1016/j.molcel.2010.12.013
Tristan, C., N. Shahani, T.W. Sedlak, and A. Sawa. 2011. The diverse functions 
of GAPDH: views from different subcellular compartments. Cell. Signal. 
23:317–323. http://dx.doi.org/10.1016/j.cellsig.2010.08.003
Valentini, G., A. De Gregorio, C. Di Salvo, R. Grimm, E. Bellocco, G. Cuzzocrea, 
and P. Iadarola. 1996. An essential lysine in the substrate­binding site of 
ornithine carbamoyltransferase. Eur. J. Biochem. 239:397–402. http://
dx.doi.org/10.1111/j.1432­1033.1996.0397u.x
Ventura, M., F. Mateo, J. Serratosa, I. Salaet, S. Carujo, O. Bachs, and M.J. 
Pujol. 2010. Nuclear translocation of glyceraldehyde­3­phosphate 
dehydrogenase is regulated by acetylation. Int. J. Biochem. Cell Biol. 
42:1672–1680. http://dx.doi.org/10.1016/j.biocel.2010.06.014
Walter, R.A., J. Nairn, D. Duncan, N.C. Price, S.M. Kelly, D.J. Rigden, and 
L.A. Fothergill­Gilmore. 1999. The role of the C­terminal region in 
phosphoglycerate mutase. Biochem. J. 337:89–95. http://dx.doi.org/ 
10.1042/0264­6021:3370089
Weinert, B.T., S.A. Wagner, H. Horn, P. Henriksen, W.R. Liu, J.V. Olsen, 
L.J. Jensen, and C. Choudhary. 2011. Proteome­wide mapping of the 
Drosophila acetylome demonstrates a high degree of conservation 
of lysine acetylation. Sci. Signal. 4:ra48. http://dx.doi.org/10.1126/ 
scisignal.2001902
Wellen, K.E., G. Hatzivassiliou, U.M. Sachdeva, T.V. Bui, J.R. Cross, and 
C.B. Thompson. 2009. ATP­citrate lyase links cellular metabolism 
to histone acetylation. Science. 324:1076–1080. http://dx.doi.org/10 
.1126/science.1164097
Yamada, K., and T. Noguchi. 1995. [Alteration of isozyme gene expression dur­
ing cell differentiation and oncogenesis]. Nippon Rinsho. 53:1112–1118.
Yang, J., S.C. Kalhan, and R.W. Hanson. 2009. What is the metabolic role of 
phosphoenolpyruvate carboxykinase? J. Biol. Chem. 284:27025–27029. 
http://dx.doi.org/10.1074/jbc.R109.040543
Yu, W., Y. Lin, J. Yao, W. Huang, Q. Lei, Y. Xiong, S. Zhao, and K.L. Guan. 
2009. Lysine 88 acetylation negatively regulates ornithine carbamo­
yltransferase activity in response to nutrient signals. J. Biol. Chem. 
284:13669–13675. http://dx.doi.org/10.1074/jbc.M901921200
Yu, H., Y. Shao, L. Gao, L. Zhang, K. Guo, C. Wu, X. Hu, and H. Duan. 2012. 
Acetylation of sphingosine kinase 1 regulates cell growth and cell­cycle 
progression. Biochem. Biophys. Res. Commun. 417:1242–1247. http://
dx.doi.org/10.1016/j.bbrc.2011.12.117
Zhang, T., S. Wang, Y. Lin, W. Xu, D. Ye, Y. Xiong, S. Zhao, and K.L. Guan. 
2012. Acetylation negatively regulates glycogen phosphorylase by 
recruiting protein phosphatase 1. Cell Metab. 15:75–87. http://dx.doi 
.org/10.1016/j.cmet.2011.12.005
Zhao, S., W. Xu, W. Jiang, W. Yu, Y. Lin, T. Zhang, J. Yao, L. Zhou, Y. Zeng, 
H. Li, et al. 2010. Regulation of cellular metabolism by protein lysine 
acetylation. Science. 327:1000–1004. http://dx.doi.org/10.1126/science 
.1179689
Zheng, L., R.G. Roeder, and Y. Luo. 2003. S phase activation of the his­
tone H2B promoter by OCA­S, a coactivator complex that contains 
GAPDH as a key component. Cell. 114:255–266. http://dx.doi.org/ 
10.1016/S0092­8674(03)00552­X
